

# *Case Study: Systemic Evaluation of Vial Container Closure System Suitability at Frozen Conditions*

- Coralie Richard, Eli Lilly and Company
- With Significant Contribution from Peter Sargent, Eli Lilly and Company

# Agenda

- Background
- Risk Assessment
  - Suitability Hazards
- Phase based strategy
  - Screening Assessment
  - Development
  - Scale Up
- Takeaways

# Background

## *Evolving needs for deep frozen storage*

- Cell/gene therapies
- Vaccines

## *Opportunities for extended expiry*

- Increased protein stability for biologics
- Establish shelf-life with limited stability knowledge

### COVID-19 VACCINE STORAGE REQUIREMENTS

**Pfizer**

**moderna**

**Johnson & Johnson**

Pfizer	Moderna	Johnson & Johnson
<p><b>PRIOR TO VIAL USE:</b></p> <ul style="list-style-type: none"> <li>• Prior to thawing, store in an ultra-cold freezer between -80°C to -60°C</li> <li>• Once thawed, the vial can be stored undiluted in two ways:               <ul style="list-style-type: none"> <li>– Up to 5 days in a refrigerator</li> <li>– No more than 30 minutes at room temperature</li> </ul> </li> </ul> <p><b>Once Vial is First Used:</b></p> <ul style="list-style-type: none"> <li>• Store between 2°C and 25°C for no more than 6 hours.</li> </ul> <p><b>DO NOT REFREEZE</b></p>	<p><b>PRIOR TO VIAL USE:</b></p> <ul style="list-style-type: none"> <li>• Prior to puncturing the vial, the product can be stored in three ways:               <ul style="list-style-type: none"> <li>– Frozen between -25°C and -15°C (Recommended unless immediate use is necessary)</li> <li>– Refrigerated between 2°C and 8°C for up to 30 days</li> <li>– Unrefrigerated for up to 12 hours</li> </ul> </li> </ul> <p><b>Once Vial is First Used:</b></p> <ul style="list-style-type: none"> <li>• Store between 2°C and 25°C for no more than 6 hours.</li> </ul> <p><b>DO NOT REFREEZE</b></p>	<p><b>PRIOR TO VIAL USE:</b></p> <ul style="list-style-type: none"> <li>• The product can be stored in two ways:               <ul style="list-style-type: none"> <li>– Refrigerated between 2°C and 8°C for no more than 3 months</li> <li>– Unrefrigerated between 9°C and 25°C for up to 12 hours.</li> </ul> </li> </ul> <p><b>Once Vial is First Used:</b></p> <ul style="list-style-type: none"> <li>• The product can be stored in two ways:               <ul style="list-style-type: none"> <li>– Refrigerated between 2°C and 8°C for up to 6 hours</li> <li>– At room temperature for up to 2 hours.</li> </ul> </li> </ul> <p><b>DO NOT REFREEZE</b></p>

©2021 American Hospital Association | www.aha.org | March 2021

# Risk Assessment: Suitability Hazards

## **Protection Risk**


- Loss of elastomer elasticity below  $T_g$
- Increased risk for breakage due to liquid expansion
- Difference of CLTE (coefficient of linear thermal expansion)

## **Performance Risk**

- Mechanical/thermal stresses of shipping
- Thermal stresses of processing streams
- In-use performance after thaw



## **Safety & Compatibility**

- Frozen conditions favorable for DP stability and E/L



(A) is an unstressed polymer; (B) is the same polymer under stress. When the stress is removed, it will return to the A configuration. (The dots represent cross-links) [Wikipedia, Elastomer](#)

# Risk Assessment: Phased Approach

Stage Description	Screen	Confirm	Develop	Scale Up
<b>Activities</b>	<ul style="list-style-type: none"> <li>Form/Fit Concerns</li> <li>Finite Element Analysis</li> </ul>	<ul style="list-style-type: none"> <li>In-Use conditions</li> <li>CT X-Ray</li> <li>Inherent Leak (HeLD)</li> </ul>	<ul style="list-style-type: none"> <li>Head Space Analysis</li> <li>Stability</li> <li>Shipping Hazards</li> </ul>	<ul style="list-style-type: none"> <li>Process Mapping</li> <li>Structural Integrity</li> </ul>
<b>Phase</b>				
<b>Focus</b>				

- *Right size the approach*
- *Gate transitions between phases*
- *Expand the system boundaries*

# Screening: Form / Fit + Computed Aided Engineering

*Form fit: Component Stack Tolerances*

Stopper Seal Commodity



Vial Commodity



*CAE / Modeling: characterize component Materials of Construction as inputs*

**Vials**


Assumed to be a rigid body

**Elastomer**

- Viscoelastic characterization  $> T_g$
- Elasto-plastic characterization  $< T_g$

**Seals**



- $T_g$
- CTE
- Poisson



# Screening: CAE

## Evaluate contact pressure

- Consider shelf life
- Consider temperature




	Contact pressure (MPa)	Contact force (N)
Maximum	1	25.7
Relaxed	0.864	22.2

# Development: CT Imaging



## *Confirm modeling assumptions via CT x-ray*

- Look for variance between normal conditions and frozen

Pre-Freeze



Frozen






# Development: CCI

## Inherent Leak Rate

- Conduct as guided by USP <1207>
- Conduct at temperature via HELD
- Focused on design risk



## Headspace Analysis


- Allows for CCI evaluation at in-use conditions
  - Incorporates temperature
  - Apply known shipping & shelf life constraints



- -78 °C, headspace underpressure
- Stopper loose elasticity, interface gaps
- CO<sub>2</sub> in headspace
- Warm up, stopper reseals
- CO<sub>2</sub> trapped

# Development: Seal Quality Test

Main Goal: Establishing the correlation between residual seal force (RSF) (seal quality test) and CCI



Developing a Readily Available Primary Packaging System for Use in an Ultra-Cold Chain for COVID19 Vaccine Global Distribution – Using a Scientific Approach

Co-presenters:  
Michael Edey, Pfizer  
Derek Duncan, Lighthouse Instruments

See Suzanne's presentation

2021 PDA Parenteral Packaging Conference

# Scale Up: Approach

## ***Shift the focus from systemic to residual risk***

- Transition from design → process
- Emphasize control strategy development
  - Consider incoming, filling, and transit
  - Incorporate 2<sup>o</sup> packaging?
- Employ statistical powering

# Scale Up: Structural Integrity

## **Hazards**

- Liquid expansion at phase change
- Freeze/thaw at shipping nodes
- Mechanical stresses
  - Vibration and Drop during shipment
  - Glass to glass contact at filling


## **DOE considerations**

- Storage Temperature/orientation
- Shipping conditions: temperature, method, e.g. dry ice
- Fill volume, CCS size
- Best outputs (RSF, CCI)

# Scale Up: Process Mapping

## Process Mapping

- Understand temperature transitions
- Build in high-volume production hazards
- Adopt a statistical approach and foundation



# Takeaways

Risk Assessment Strategy  
Use a right sized, phase approach

## **Screen** for Form/Fit issues at 'standard' conditions


- Machinability studies
- Stacked Tolerance Analysis

## **Confirm & Develop** frozen use conditions

- Identify lower temp. bound in storage and shipping
- Understand supply chain risk points
  - Impact of Shipping Hazards
  - Temperature transitions

## **Apply a world view in the** **scale up** process

- Transition to outcomes thinking
- Propagation of stresses means propagation of risk



# Acknowledgments

- Craig Kemp
- Craig Goldhammer
- Lin Li
- Michael Foubert
- Vijay Sharma
- Lei Li
- Mark Beidelschies
- Michael Boquet
- David Lyngholm

# Using Helium Leak Detection CCI Testing to Inform Container Closure System Design

## A Prefilled Syringe Case Study

*Container Closure Integrity: Regulations, Test  
Methods, Application*

*Coralie Richard*

*Lei Li*

*Eli Lilly and Company*




# Outline

- ~~Overview of Helium Leak Detection (HeLD)~~
- Method development for syringes
  - Fixture design
  - Helium charging
- Applications of Helium Leak Detection
  - Determination of inherent package integrity
  - Evaluation of syringe system and sub-system design
  - Assessment of container closure robustness


# Introduction – Helium Leak Detection

- **Sensitivity & Quantitative**
  - Mass spectrometer as detector
- **Selectivity**
  - Low atmospheric interference: Helium in the atmosphere (~5 ppm)
  - Do need to minimize lab ambient helium and permeation
- **Flows through cracks ~2.7x faster than air**



Leak Detection Associates, Blackwood, NJ

# Prefilled Syringe System



## “Weak links”

- Plunger-barrel seal
- Needle shield seal
  - Needle tip seal
  - Glued needle stem
  - Needle shield/syringe head




# Preliminary Testing

1. **Filling:** syringes charged with helium and plungered in a glove box





2. **Testing:** filled syringe is placed in a sample chamber for testing

- A plunger rod is used to retain plunger during testing



# Potential Interferences

- **Desorption** of exterior surface-adsorbed helium
- Helium **permeation**




# Preliminary Results

- ✓ **Estimated overall leakage rate**
  - Results can be artificially high due to surface desorption and permeation
- ✓ **Demonstrated conformance to MALL**

## Improvement Needs

- Reduce helium background noise to measure “true” leakage rate
  - Exterior surface desorption
  - Permeation
- Need to evaluate sealing capability of critical seal elements and sub-systems




# Method Improvement Strategy

- ❑ “Fast and Clean” helium charging
  - **Fast:** allow testing to start prior to significant permeation
  - **Clean:** eliminate helium contact with interfering sample surfaces
  
- ❑ “Divide and Conquer” critical seal elements
  - Isolate critical seal elements for independent assessment





**Key Enabler: Sample Fixture Design**

# Testing Fixture Design






# Testing Fixture Design



**Needle Shield – Barrel head Seal**




**Needle Stem Seals**

# Evaluation of Needle Shield – Barrel Seal


## A combination of 3 seal elements

- Needle shield – Syringe head
  - Needle tip – Needle shield
  - Glued staked needle
- Critical to product sterility and formulation content protection




Leakage Rate  $\leq 8 \times 10^{-11}$  atm-cc/sec

- Confirm to MALL for preserving sterility and product formulation content



- **Physically mated (compression) seal**
  - Critical to needle stem sterility protection
  - Contributes to DP compartment seal





Leakage Rate  $\leq 6 \times 10^{-7}$  atm-cc/sec

- Confirm to MALL for preserving sterility

# Evaluation of Needle Stem Seals

- Glued (physicochemically bonded) at the base
- Physically mated (compression) seal at the tip
  - Not definitive sterility barriers
  - Poor seals may result to product loss or injection issues




Leakage Rate  $\leq 2 \times 10^{-9}$  atm-cc/sec

- Confirm to MALL for preserving sterility and product formulation content


- DP compartment (Plunger & Needle Shield)  $\leq 5 \times 10^{-10}$  atm-cc/sec
- Needle stem compartment  $\leq 6 \times 10^{-7}$  atm-cc/sec
- All individual critical seals conform to MALL

**$8 \times 10^{-11}$  atm-cc/sec**

“Layered” seal design in needle shield significantly lowers overall leakage rate  
 – Added protection to drug product



**$4 \times 10^{-10}$  atm-cc/sec**



**$2 \times 10^{-9}$  atm-cc/sec**



**$6 \times 10^{-7}$  atm-cc/sec**

The needle shield – barrel head seal is the weakest among all seals

**Package Integrity was verified for preserving sterility and formulation content**


# Design Robustness: Plunger Ribs

- Each plunger rib assessed individually for sealing capability
  - Assessed by compromising 2 of the 3 ribs, leaving 1 intact rib
  - Evaluate impact of potential plunger molding defects




- Each individual rib provides adequate seal
- Rib #1 provides superior sealing performance

# Design Robustness: Fiber Interference





- Fiber Interference between plunger rib and barrel
- Industry needs a practical means to fabricate and characterize sub-micron size defects
- Assess impact of interfering fibers of various sizes



# Design Robustness: Fiber Interference

**Helium Leakage Rates**



- Presence of interfering fibers could compromise plunger seal integrity
- Interfering fibers provide a practical means for fabricating sub-micron defects
  - Enable development of other CCI testing technologies




# Potential Opportunities

## Needle Shield Gap Study

- How much needle shield movement until it leaks?
- Use spacer to create controlled gaps

Spacer



## “CCI Capability”

- Multiple Lots
- Cpk of leakage rate?
- Correlation with dimensional Cpk

## Component aging study

How does the seal performance change over time?

# Conclusions

- ❑ Understand Instruments + Methods + Results
  - Not a black box
  - Fixture design and helium charging critical for method development
  
- ❑ Understand your CCS
  - Inform packaging component selection and system design
  - Assess container closure robustness against design, process variability
  - Demonstrate conformance to MALL

# References